Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318862 | 0.84 | DHFR (0.56) | PIK3CAGRM4TNFDHFR | |
| SCHEMBL6318945 | 0.79 | TNF (0.44) | PIK3CAGRM4TNFDHFR | |
| SCHEMBL6315288 | 0.77 | PDGFRB (0.49) | PIK3CAGRM4TNF | |
| SCHEMBL6313126 | 0.77 | HTR3A (0.52) | PIK3CADHFR | |
| SCHEMBL6315310 | 0.76 | ADORA1 (0.45) | PIK3CATNFDHFR | |
| SCHEMBL6313731 | 0.76 | PIK3CA (0.41) | PIK3CAGRM4TNFSYKDHFR | |
| SCHEMBL6313258 | 0.76 | DYRK1A (0.43) | TGFBR1PIK3CAGRM4TNFDHFR | |
| SCHEMBL6312244 | 0.76 | CYP1A2 (0.52) | PIK3CATNFCYP1A2 | |
| SCHEMBL6312550 | 0.75 | CA12 (0.56) | PIK3CAGRM4TNFCYP1A2 | |
| SCHEMBL6313300 | 0.74 | ABCG2 (0.46) | PIK3CAGRM4TNFSYKDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | CDC7 2635/4885TRPA1 1962/4885TGFBR1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.